An observational study in Fallopian Tube Carcinoma, Hereditary Breast and Ovarian Cancer Syndrome and Ovarian Carcinoma, sponsored by Gynecologic Oncology Group. Withdrawn at 1 site in United States. Open to female participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2024-08-21.
Sponsored by Gynecologic Oncology Group · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Fallopian Tube Neoplasms by Gynecologic Oncology Group — none open to participants now, none under way, none of them phase 3. Fallopian Tube Neoplasms · Gynecologic Oncology Group.
Among the 41 studies in Fallopian Tube Neoplasms by Gynecologic Oncology Group, this one is one of 6 that started in 2011, is one of 9 observational ones, and was the 38th registered.
835 studies on the registry are indexed under Fallopian Tube Neoplasms; 128 are open to participants now.
Browse Fallopian Tube Neoplasms studies →None of the 41 studies in Fallopian Tube Neoplasms by Gynecologic Oncology Group is open now. The open studies under Fallopian Tube Neoplasms, anywhere →
Of the 104 Fallopian Tube Neoplasms studies recruiting now, 85 (82%) set no upper age limit and 10 (10%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.
This study: 30 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 1992; this study’s year is marked. 6 started in 2011.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 30 across the 27 interventional studies, 275 across the 9 observational. Of the 30 that completed or were terminated, 12 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gynecologic Oncology Group is the lead sponsor of 188 studies on the registry; 1 is open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 41 studies in Fallopian Tube Neoplasms by Gynecologic Oncology Group, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This research trial collects information about types of treatment and the cost of these procedures in women with elevated genetic risk for ovarian cancer who participated on the Gynecology Oncology Group (GOG)-0199 trial. Gathering information about women at elevated genetic risk for ovarian cancer may help doctors learn more about risk reduction procedures and the cost of these procedures.
PRIMARY OBJECTIVES:
I. To estimate the cost-effectiveness, defined as cost per quality-adjusted life-year saved, of risk-reducing salpingo-oophorectomy (RRSO) versus ovarian cancer screening (OCS) for women at elevated genetic risk of ovarian cancer over a five-year period, using data from GOG-0199 to model survival.
SECONDARY OBJECTIVES:
I. To estimate the cost-effectiveness, defined as cost per quality-adjusted life-year saved, of RRSO versus OCS for women at elevated genetic risk of ovarian cancer over a lifetime, using stage-specific cohorts and population-based data to model long-term survival. (Exploratory) II. To use value of information (VOI) methodology to set future research priorities aimed at developing evidence-based approaches to the management of women who are at elevated genetic risk of ovarian cancer. (Exploratory)
OUTLINE:
Outcome data, such as incidence and stage at diagnosis of ovarian, fallopian tube, and peritoneal cancers; number and timing of screening and serum tests performed; number and timing of pelvic ultrasounds performed; surgical procedures performed; cancer-specific and overall survival (if available); and the incidence, type, and grade of significant adverse events, are collected from the Gynecologic Oncology Group (GOG)-0199 records and analyzed. Cost of each medical intervention is also estimated.
Patients with ovarian cancer who participated in GOG-0199
Inclusion Criteria:
Outcome data, such as incidence and stage at diagnosis of ovarian, fallopian tube, and peritoneal cancers; number and timing of screening and serum tests performed; number and timing of pelvic ultrasounds performed; surgical procedures performed; cancer-specific and overall survival (if available); and the incidence, type, and grade of significant adverse events, are collected from the Gynecologic Oncology Group (GOG)-0199 records and analyzed. Cost of each medical intervention is also estimated.
Procedure: Evaluation of Cancer Risk Factors · Other: Medical Chart Review · Other: Study of Socioeconomic and Demographic Variables
Ancillary studies
Also known as: cancer risk factors evaluation
Ancillary study
Also known as: Chart Review
Ancillary studies
Cost-effectiveness of RRSO versus OCS
Incidence and stage at diagnosis of ovarian, fallopian tube, and peritoneal cancers in the OCS arm and in the RRSO arm will be collected. This information will be obtained from the CANCER UPDATE FORM (CA-0199) and the Ovarian Surgery Form (C-0199). Summary of the number and timing of screening serum tests, pelvic ultrasound, and surgery procedures will be used to calculate costs, and will be incorporated into the model of Markov stage that corresponds to the study timepoint at which these studies were performed.
Time frame: 6 months
Start is estimated for Jan 2011; primary completion for Jan 2016, 60 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.